Azelastine — potential risks, side effects and interaction with alcohol

Effective | toxic

Names under which azelastine is available: the international nonproprietary name is azelastine, and the Latin spelling is azelastine; the active ingredient in medicinal products is usually present as azelastine hydrochloride — azelastine hydrochloride, azelastine HCl. The main dosage forms are metered-dose nasal sprays containing 0.1% or 0.15% and 0.05% eye drops. Brand names include Allergodil, Astelin, Astepro and various products marketed as Azelastine Hydrochloride. Combination nasal products containing azelastine and fluticasone propionate are marketed under the name Dymista and as generic equivalents. A patient may fail to recognise duplicate exposure to azelastine when using a separate antihistamine spray together with a combination spray containing fluticasone.

Why azelastine is considered harmless and where the real risk begins: azelastine is often perceived as an ordinary topical allergy spray that acts only in the nose and cannot affect the central nervous system. This is incorrect: after intranasal administration, the drug is systemically absorbed, and its elimination half-life is approximately 22–25 hours; the active metabolite desmethylazelastine persists for even longer. Repeated doses may therefore maintain systemic exposure for 24 hours or more. The main everyday risk is drowsiness, reduced attention and slowed psychomotor reactions, which a person may not associate with a nasal spray. Driving, operating machinery and the simultaneous use of alcohol, sleeping pills, sedating antihistamines, tranquillisers, opioids and other central nervous system depressants are particularly dangerous.

Side effects during the first hours and days of use: the most characteristic reaction to intranasal azelastine is a pronounced bitter taste caused by the solution running down into the nasopharynx. Burning, pain and discomfort in the nose, bouts of sneezing, mucosal dryness, pharyngitis, headache, nausea, dry mouth, dizziness, fatigue and drowsiness may also occur. Nosebleeds are associated with irritation of the mucosa, incorrect direction of the spray towards the nasal septum, injury caused by the nozzle and repeated use when the mucosa is dry or the epithelium is already damaged. Clinically significant drowsiness may occur after the first doses and result in a road traffic or occupational injury. Rare but dangerous reactions include generalised hypersensitivity, swelling of the face, tongue or larynx and difficulty breathing. With eye drops, transient burning and stinging in the eyes, headache and a bitter taste are observed much more frequently; eye drops must not be administered into the nose, swallowed or used as an injectable solution.

Side effects with prolonged and repeated use: there is no convincing evidence of pronounced cumulative hepatotoxicity, nephrotoxicity, cardiotoxicity, hormonal disorders or dependence when azelastine is used topically at standard doses. It is therefore incorrect to attribute liver, kidney or heart damage to it automatically. The genuine long-term problems are mainly persistent mucosal irritation, dryness, recurrent nosebleeds, a chronic unpleasant taste, headache and continuing drowsiness. Because azelastine and its metabolite have long elimination half-lives, systemic effects may persist with regular use, particularly when the dose is exceeded. Tolerance and drug dependence are not characteristic of azelastine, and there is no classic withdrawal syndrome. However, the drug suppresses allergy symptoms but does not eliminate the source of sensitisation, infection, polyps, anatomical obstruction or drug-induced rhinitis. Prolonged self-treatment may mask a disease mistakenly assumed to be an allergy. A long-term study of a combination azelastine and fluticasone spray found no septal ulcers or perforation over one year, but these results cannot automatically be extrapolated to incorrect spraying, damaged mucosa or uncontrolled dose escalation.

Contraindications and high-risk groups: confirmed hypersensitivity to azelastine or to any component of the specific solution is an absolute contraindication. A nasal spray must not be used in a child younger than the age specified in the instructions for the particular concentration and commercial formulation, as age restrictions vary. Drivers, equipment operators, people working at height and patients whose activities require sustained concentration are at increased risk of drowsiness and injury. In older adults and in patients with pre-existing dizziness, impaired balance, cognitive disorders or simultaneous use of psychotropic and sedating drugs, even moderate drowsiness increases the likelihood of falls. When the mucosa is dry, nosebleeds recur or there has been recent nasal surgery or trauma, spraying may worsen irritation and bleeding. Eye drops are not intended to treat irritation caused by contact lenses; the lenses should be removed before instillation in accordance with the instructions for the specific product. Pregnancy and breastfeeding are not grounds for an automatic prohibition, but they require assessment of the expected benefit, the dosage form and systemic exposure.

Dangerous interactions: combining intranasal azelastine with alcohol should be considered highly undesirable. Manufacturers explicitly warn that alcohol may further reduce alertness, attention and central nervous system performance. Benzodiazepines, sleeping pills, first-generation sedating antihistamines, opioid analgesics, certain antipsychotics, anticonvulsants, muscle relaxants, cannabinoids and other substances that cause drowsiness create a similar risk. The consequence may not be a specific form of “azelastine poisoning”, but rather an additive sedative effect leading to impaired coordination, driving errors, falls and injuries. In a study of oral azelastine, cimetidine increased its maximum concentration and overall exposure by approximately 65%; the clinical significance of this interaction for intranasal use has not been established, but the combination may intensify systemic reactions in sensitive patients. Erythromycin, ranitidine and theophylline did not produce significant pharmacokinetic interactions in studies. A separate problem is hidden duplication of azelastine when a standalone nasal spray is used simultaneously with a combination azelastine + fluticasone product.

Patient errors: the most common mistake is to assume that a topical drug has no systemic effects at all and to drive immediately after the first dose. Some patients increase the number of sprays when their nose is blocked, without understanding that an antihistamine does not instantly eliminate mechanical obstruction. Another error is tilting the head back and inhaling the medication forcefully: the solution runs down into the throat, intensifying the bitter taste, nausea and systemic swallowing of the drug. The nozzle is often directed towards the nasal septum, which increases the risk of irritation and bleeding. It is dangerous to use Allergodil, another generic azelastine product and Dymista simultaneously without recognising that they contain the same active ingredient. Drinking alcohol in the evening while using the spray is mistakenly considered acceptable because the medicine is “not in tablet form”. It is also incorrect to suppress symptoms for months without clarifying the cause of rhinitis: an infection, polyposis, vasomotor rhinitis, dependence on decongestants or another disease may be mistaken for an allergy.

Overdose and poisoning: no precise single toxic dose has been established for intranasal azelastine in humans at which severe poisoning is guaranteed to occur. One standard 0.1% bottle may contain approximately 30 mg of azelastine hydrochloride. According to the official prescribing information, accidental use of the contents of a bottle by an adult is unlikely to cause severe toxicity apart from increased drowsiness, but this does not mean that swallowing the solution is safe. With a substantial overdose, the most likely effects are pronounced drowsiness, lethargy, dizziness, impaired coordination, nausea and a reduced ability to drive safely. In a child, dangerous exposure may occur with a smaller absolute amount because of lower body weight. The risk increases when azelastine is combined with alcohol, sleeping pills, tranquillisers, opioids and other central nervous system depressants. There is no specific antidote; treatment is symptomatic and supportive. After a significant amount has been swallowed, or if unusual drowsiness, impaired consciousness, breathing or coordination occurs, further deterioration must not be awaited — urgent toxicological assessment is required. Vomiting should not be induced without medical advice.

Safe integrative alternative to azelastine: in allergic rhinitis, azelastine may be replaced or supplemented with agents that affect not only H1 receptors, but also mast-cell degranulation, leukotriene-mediated inflammation, the eosinophilic response, the condition of the mucosa and associated bronchial hyperreactivity. Such a regimen is selected according to the clinical phenotype, because isolated rhinitis, rhinosinusitis and allergic respiratory disease require different combinations of agents.

Allergy Mixture LH is considered the principal systemic antiallergic alternative. Its purpose is to reduce the overall severity of the allergic reaction, itching, sneezing, rhinorrhoea, mucosal swelling and other manifestations of hypersensitivity. Unlike azelastine, which primarily blocks the effect of histamine already released at H1 receptors, a complex herbal regimen may act on several components of allergic inflammation. Complete replacement is most realistic in mild and stable disease. In pronounced oedema, severe airway obstruction or a rapidly developing systemic allergic reaction, herbal products must not delay necessary emergency treatment.

Kaempferia parviflora is intended to act on the early phase of the IgE-dependent allergic response. In experimental models, the polymethoxyflavones of Kaempferia parviflora suppressed mast-cell degranulation, reduced membrane expression of FcεRI and decreased phosphorylation of Syk, one of the key enzymes involved in intracellular signal transmission after an allergen binds to IgE. This pharmacologically distinguishes Kaempferia from azelastine: azelastine primarily blocks the effect of histamine, whereas Kaempferia may potentially reduce the release of allergy mediators itself. However, these mechanistic findings cannot yet be regarded as evidence of full clinical equivalence to an intranasal antihistamine.

Boswellia serrata is included in cases of leukotriene-dependent inflammation, mucosal oedema, bronchial hyperreactivity and allergic rhinitis combined with an asthmatic component. Boswellic acids, particularly AKBA, are associated with inhibition of the 5-lipoxygenase pathway and reduced formation of pro-inflammatory leukotrienes. Small clinical studies of Boswellia preparations and combined extracts have shown reductions in signs of airway inflammation and the need for inhaled therapy, but the evidence base remains substantially smaller than that for registered intranasal antihistamines. Boswellia does not suppress sneezing and rhinorrhoea as rapidly as azelastine, but it is pharmacologically more relevant in leukotriene-driven, bronchial and eosinophilic phenotypes.

When nasal symptoms predominate, Rhinitis and Rhinosinusitis Mixture LH is used together with intranasal ABP-153. This combination is intended for allergic rhinitis and the rhinosinusitis phenotype, when nasal congestion, mucosal oedema, rhinorrhoea, postnasal drainage and a tendency towards inflammation of the paranasal sinuses are present. Topical use of ABP-153 should be carried out carefully, without injuring the nasal septum and without administration in cases of individual intolerance to its components. Purulent discharge, unilateral pain, high fever, pronounced facial swelling or suspected bacterial complications require diagnostic assessment rather than symptomatic topical treatment alone.

Pinellia ternata must remain part of the regimen in allergic inflammation of the respiratory tract, bronchial hyperreactivity, cough, eosinophilic inflammation and mucus hypersecretion. It is particularly appropriate when allergic rhinitis is combined with an asthmatic or bronchitic phenotype and nasal symptoms are accompanied by cough, a sensation of mucus, difficulty clearing secretions or episodes of bronchial obstruction. Pinellia is not a direct analogue of an H1 blocker and should not be judged solely by how quickly it relieves sneezing. Its role is in correcting a respiratory phenotype characterised by excessive mucus production and bronchial reactivity. Only standardised and properly processed raw material should be used: unprocessed Pinellia ternata contains irritating constituents and is not intended for self-administration.

Bronchial Asthma Type 2 LH is used when allergic rhinitis is combined with Th2-driven and eosinophilic bronchial asthma. This clinical situation is not limited to excess histamine: IL-4, IL-5, IL-13, eosinophils, mast cells and cysteinyl leukotrienes are involved in the inflammatory process. Azelastine may therefore reduce nasal symptoms but does not control inflammation in the lower airways. During an episode of breathlessness, a reduction in peak expiratory flow, nocturnal symptoms or the need for frequent bronchodilator use, a herbal regimen does not replace emergency inhaled therapy and maintenance treatment for asthma.

Bolus for asthma with difficult-to-expectorate sputum is added in cases of thick sputum, unproductive cough, a sensation of bronchial obstruction and difficulty clearing the airways. Its role is not in treating isolated sneezing, but in the comprehensive correction of an asthmatic or bronchitic phenotype with hypersecretion and impaired sputum clearance. Increasing shortness of breath, cyanosis, falling oxygen saturation, haemoptysis or inability to expectorate sputum requires urgent medical attention.

Thus, the sequence of integrative selection is as follows: Allergy Mixture LH — the main systemic antiallergic alternative; Kaempferia parviflora — suppression of IgE–FcεRI–Syk-dependent mast-cell degranulation; Boswellia serrata — reduction of 5-LOX- and leukotriene-dependent inflammation; Rhinitis and Rhinosinusitis Mixture LH together with intranasal ABP-153 — for the nasal and rhinosinusitis phenotype; Pinellia ternata — for respiratory allergy, cough, bronchial hyperreactivity and mucus hypersecretion; Bronchial Asthma Type 2 LH — for Th2-driven and eosinophilic asthma; Bolus for asthma with difficult-to-expectorate sputum — for thick sputum and bronchial obstruction.

The actual effectiveness of azelastine and prescribing errors: azelastine is genuinely effective in seasonal and perennial allergic rhinitis. It reduces sneezing, itching, watery discharge and nasal congestion, and the nasal formulation may begin to act within approximately 15–30 minutes. This advantage is particularly important when rapid symptomatic relief is required. However, azelastine does not eliminate the cause of sensitisation, remove the allergen, treat polyposis, bacterial sinusitis or anatomical obstruction, or control bronchial inflammation in asthma. Its effect remains predominantly symptomatic. A combination of azelastine with intranasal fluticasone is usually more effective than either component alone in moderate-to-severe rhinitis, but it also adds the risks and limitations of a nasal glucocorticosteroid.

A common medical error is to prescribe azelastine for any form of chronic nasal congestion without confirming an allergic or vasomotor phenotype. In unilateral obstruction, polyps, a deviated nasal septum, a chronic bacterial process or medication-induced rhinitis, an antihistamine spray may provide only partial and temporary improvement while delaying the correct diagnosis. Other errors include failing to take sedating drugs and alcohol into account, not explaining the correct spraying technique, not asking about nosebleeds and prescribing several products containing azelastine simultaneously. Azelastine should also not be used to treat cough, bronchial obstruction or an asthma attack merely because the condition is allergic in nature.

Safety monitoring during treatment: during the first few days, drowsiness, dizziness, reduced concentration, lethargy and impaired coordination should be assessed. Until the individual response is known, patients must not drive, operate moving machinery or perform activities in which an error could cause injury. The condition of the nasal mucosa should be monitored: persistent burning, pronounced dryness, crusting, recurrent bleeding and local pain require assessment of the spraying technique, reduction of the irritating burden or discontinuation of the drug.

With standard topical use, regular laboratory monitoring of liver function, kidney function or the complete blood count is generally not required, because characteristic clinically significant organ toxicity has not been established for azelastine. Monitoring should be guided by symptoms and comorbidities rather than prescribed automatically. Immediate discontinuation and emergency care are required in the event of swelling of the tongue, lips or larynx, difficulty breathing, generalised urticaria, impaired consciousness, unusually pronounced drowsiness, sudden severe impairment of coordination or ingestion of a significant amount of the solution by a child. Persistent congestion, purulent discharge, facial pain, loss of smell, wheezing or nocturnal coughing episodes require reconsideration of the diagnosis.

Correct discontinuation of azelastine: azelastine can be stopped immediately; gradual dose reduction is usually not required. The drug does not cause classic physical dependence, a withdrawal syndrome or medication-induced rhinitis of the type associated with vasoconstrictive α-adrenergic agonists. After treatment is stopped, sneezing, itching, rhinorrhoea and nasal congestion may return if exposure to the allergen continues. This represents recurrence of the underlying disease, not evidence of dependence on the spray.

With prolonged use of a combination azelastine + fluticasone product, the rules for discontinuation are determined not only by azelastine, but also by the presence of a topical glucocorticosteroid, the severity of rhinitis and coexisting asthma. Stopping all antiallergic agents without medical guidance during a period of high allergen exposure may lead to recurrence of symptoms. Transition to an integrative regimen is more appropriately carried out with consideration of the clinical phenotype and the course of the condition, rather than by replacing one agent with another on the day of a severe exacerbation.

A rational approach to treatment: azelastine is justified when rapid reduction of allergic rhinitis symptoms is required and the person does not experience clinically significant drowsiness, mucosal irritation or nosebleeds. Its advantage is rapid and reasonably predictable local action. Its limitations are the predominantly symptomatic nature of its effect, systemic absorption, sedation in some patients, an unpleasant taste, mucosal irritation and the danger of combining it with alcohol and other central nervous system depressants.

In mild and stable allergic rhinitis, a systemic antiallergic herbal regimen may be used together with local support for the mucosa. In the rhinosinusitis phenotype, it is appropriate to supplement it with agents targeting inflammation of the nose and paranasal sinuses. In cough, mucus hypersecretion, bronchial hyperreactivity and eosinophilic inflammation, Pinellia ternata must remain part of the regimen; in Th2 asthma and difficult-to-expectorate sputum, the corresponding specialised complexes are used. Azelastine and herbal products may be used together temporarily when rapid symptom control is required, followed by a reduction in pharmacological burden. In severe asthma, anaphylaxis, pronounced respiratory failure or an infectious complication, an integrative regimen must not replace emergency and aetiological treatment.

If you have questions about the topic of this article, you may ask a clinical pharmacologist in the comments or book an appointment using the following link: https://asiabiopharm.com/konsultaciii/